Almac Sciences, a member of the Almac Group, has expanded its peptide API manufacturing facility at the company’s global headquarters in Craigavon, UK.

The 28,000 square feet GMP facility more than doubles peptide API manufacturing capacity for Almac Sciences.  It will enhance synthesis, purification and isolation capabilities and meet anticipated demand for clinical development and commercial products.

The new peptide API manufacturing facility significantly grows our portfolio of client APIs and is the latest stage of a wider development and manufacturing expansion initiative for Almac Sciences. The current expansion of its small molecule API facility is well under construction and will enable manufacture from 100s kg to metric tonne scale.  The business has also opened a new technology development centre housing its biocatalysis, flow chemistry and radiolabelling facilities, installed additional small molecule API GMP reactors, and opened a dedicated chemical warehouse.

These developments are part of Almac’s global investment programme announced in June 2022. 

Alastair Hay, VP Peptides said: “Our continued expansion ensures that we remain the global leaders in our industry, giving our clients the best possible offering from Almac.”

Almac has a proven track record and expertise in small molecule and peptide API manufacturing from pre-clinical to commercial scale and has developed long-established relationships from pharma and biotech clients offering comprehensive end-to-end development and manufacturing solutions.